Open Access

Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’

  • Thomas P. Hellyer1Email author,
  • Niall H. Anderson2,
  • Jennie Parker3,
  • Paul Dark4,
  • Tina Van Den Broeck5,
  • Suveer Singh6,
  • Ronan McMullan7,
  • Ashley M. Agus8,
  • Lydia M. Emerson9,
  • Bronagh Blackwood9,
  • Savita Gossain10,
  • Tim S. Walsh11,
  • Gavin D. Perkins12,
  • Andrew Conway Morris13,
  • Daniel F. McAuley2, 8, 14 and
  • A. John Simpson1
Trials201617:465

https://doi.org/10.1186/s13063-016-1594-8

Received: 30 August 2016

Accepted: 13 September 2016

Published: 26 September 2016

The original article was published in Trials 2016 17:318

Erratum

Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than 10^4 colony forming units/ml. These should read greater OR EQUAL to 10^4 colony forming units/ml. The error is in the abstract and in the intervention sections.

In the abstract, please replace:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [>]104 colony forming units per millilitre (CFU/ml).

With the following correct version:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [≥]104 colony forming units per millilitre (CFU/ml).

In the Interventions, please replace:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at [>]104 colony forming units per ml (CFU/ml)(13).

With the following correct version:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at [≥]104 colony forming units per ml (CFU/ml)(13).

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Cellular Medicine, Newcastle University
(2)
Centre for Population Health Sciences, University of Edinburgh, Medical School
(3)
Newcastle Clinical Trials Unit, Newcastle University
(4)
Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Sciences Centre & Intensive Care Unit, Salford Royal NHS Foundation Trust
(5)
Becton Dickinson Biosciences
(6)
Intensive Care Unit, Chelsea and Westminster Hospital, Imperial College London
(7)
Department of Medical Microbiology, Kelvin Building, The Royal Hospitals
(8)
Northern Ireland Clinical Trials Unit, Elliot Dynes Building, The Royal Hospitals
(9)
Centre for Experimental Medicine, Queen’s University Belfast
(10)
Public Health Laboratory, Heart of England NHS Foundation Trust
(11)
MRC Centre for Inflammation Research, University of Edinburgh
(12)
University of Warwick and Heart of England NHS Foundation Trust
(13)
Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge Biomedical Campus
(14)
Regional Intensive Care Unit, Royal Victoria Hospital

Reference

  1. Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. Trials. 2016;17:318.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement